Latin America Erythropoietin Drugs Market Size & Outlook

The erythropoietin drugs market in Latin America is expected to reach a projected revenue of US$ 440.1 million by 2030. A compound annual growth rate of 2.7% is expected of Latin America erythropoietin drugs market from 2024 to 2030.
Revenue, 2023 (US$M)
$364.6
Forecast, 2030 (US$M)
$440.1
CAGR, 2024 - 2030
2.7%
Report Coverage
Latin America

Latin America erythropoietin drugs market highlights

  • The Latin America erythropoietin drugs market generated a revenue of USD 364.6 million in 2023.
  • The market is expected to grow at a CAGR of 2.7% from 2024 to 2030.
  • In terms of segment, biosimilars was the largest revenue generating type in 2023.
  • Biosimilars is the most lucrative type segment registering the fastest growth during the forecast period.
  • Country-wise, Mexico is expected to register the highest CAGR from 2024 to 2030.

Latin America data book summary

Market revenue in 2023USD 364.6 million
Market revenue in 2030USD 440.1 million
Growth rate2.7% (CAGR from 2023 to 2030)
Largest segmentBiosimilars
Fastest growing segmentBiosimilars
Historical data covered2018 - 2022
Base year for estimation2023
Forecast period covered2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationBiologics, Biosimilars
Key market players worldwideJohnson & Johnson, Novartis AG ADR, Teva Pharmaceutical Industries Ltd, Amgen Inc, Roche Holding AG ADR, Intapp Inc, Dr Reddy's Laboratories Ltd ADR, LG Chem, Sun Pharmaceutical Industries, Biocon

Other key industry trends

  • In terms of revenue, Latin America region accounted for 5.2% of the global erythropoietin drugs market in 2023.
  • Globally, North America is projected to lead the regional market in terms of revenue in 2030.
  • Asia Pacific is the fastest growing regional market and is projected to reach USD 2,036.9 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Erythropoietin Drugs Market Companies

Name Profile # Employees HQ Website

Latin America erythropoietin drugs market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to erythropoietin drugs market will help companies and investors design strategic landscapes.


Biosimilars was the largest segment with a revenue share of 57.13% in 2023. Horizon Databook has segmented the Latin America erythropoietin drugs market based on biologics, biosimilars covering the revenue growth of each sub-segment from 2018 to 2030.


  • Latin America Erythropoietin Drugs Type Outlook (Revenue, USD Million, 2018-2030)
    • Biologics
    • Biosimilars
  • Latin America Erythropoietin Drugs Product Outlook (Revenue, USD Million, 2018-2030)
    • Erythropoietin
    • Darbepoetin-alfa
  • Latin America Erythropoietin Drugs Application Outlook (Revenue, USD Million, 2018-2030)
    • Cancer
    • Renal Diseases
    • Neurology
    • Other Applications

Reasons to subscribe to Latin America erythropoietin drugs market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Latin America erythropoietin drugs market databook

  • Our clientele includes a mix of erythropoietin drugs market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of continent-level data and insights on the Latin America erythropoietin drugs market , including forecasts for subscribers. This continent databook contains high-level insights into Latin America erythropoietin drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Latin America erythropoietin drugs market size, by country, 2018-2030 (US$M)

Latin America Erythropoietin Drugs Market Outlook Share, 2023 & 2030 (US$M)

Latin America erythropoietin drugs market size, by country, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more